Tempest Therapeutics Inc. (TPST)
NASDAQ: TPST
· Real-Time Price · USD
6.88
-0.02 (-0.29%)
At close: Jun 17, 2025, 10:23 AM
-0.29% (1D)
| Bid | 6.86 |
| Market Cap | 25.34M |
| Revenue (ttm) | 486K |
| Net Income (ttm) | -44.8M |
| EPS (ttm) | -18.04 |
| PE Ratio (ttm) | -0.38 |
| Forward PE | -0.64 |
| Analyst | Hold |
| Ask | 6.98 |
| Volume | 22,049 |
| Avg. Volume (20D) | 114,274 |
| Open | 6.90 |
| Previous Close | 6.90 |
| Day's Range | 6.78 - 6.95 |
| 52-Week Range | 5.36 - 39.00 |
| Beta | -2.33 |
About TPST
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TPST
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TPST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 days ago
-15.88%
Tempest Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
1 week ago
+15.07%
Tempest Therapeutics shares are trading higher after the company announced it received orphan drug designation from the EMA for its amezalpat for the treatment of patients with hepatocellular carcinoma
